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ABSTRACT
The introduction of exogenous DNA in human
somatic cells results in a frequency of random inte-
gration at least 100-fold higher than gene targeting
(GT), posing a seemingly insurmountable limitation
for gene therapy applications. We previously
reported that, in human cells, the stable over-
expression of the Saccharomyces cerevisiae Rad52
gene (yRAD52), which plays the major role in yeast
homologous recombination (HR), caused an up to
37-fold increase in the frequency of GT, indicating
that yRAD52 interacts with the double-strand break
repair pathway(s) of human cells favoring homolo-
gous integration. In the present study, we tested the
effect of the yRad52 protein by delivering it directly
to the human cells. To this purpose, we fused the
yRAD52 cDNA to the arginine-rich domain of the
TAT protein of HIV (tat11) that is known to
permeate the cell membranes. We observed that a
recombinant yRad52tat11 fusion protein produced
in Escherichia coli, which maintains its ability to
bind single-stranded DNA (ssDNA), enters the cells
and the nuclei, where it is able to increase both
intrachromosomal recombination and GT up to 63-
and 50-fold, respectively. Moreover, the non-
homologous plasmid DNA integration decreased
by 4-fold. yRAD52tat11 proteins carrying point
mutations in the ssDNA binding domain caused a
lower or nil increase in recombination proficiency.
Thus, the yRad52tat11 could be instrumental to
increase GT in human cells and a ‘protein delivery
approach’ offers a new tool for developing novel
strategies for genome modification and gene
therapy applications.
INTRODUCTION
In mammalian cells, when a linear double-stranded DNA
fragment sharing perfect homology with a target chromo-
somal locus is transfected into the cell, it can be integrated
at the speciﬁc locus by homologous recombination (HR);
this event is referred to as gene targeting (GT; 1). Two
important known applications of GT in somatic cells are
generation of ‘knockouts’, that determines the loss-of-
function of that particular gene, and of ‘knock-ins’,
wherein a mutated allele is corrected back to the
wild-type sequence or a new mutation is introduced (2).
A major limitation to apply GT strategy in human cells is
given by the integration of exogenous DNA at random
sites by non-homologous recombination (random integra-
tion: RI), an occurrence 100–1000 times more frequent
than HR (3). This represents a severe drawback in the
current gene therapy experimentation.
Several eﬀorts have been made to increase in mamma-
lian cells the frequency of GT over RI, by modifying the
length of homology between vector and locus, by inducing
a DNA double-strand break at the target locus, or by
overexpressing recombination proteins (4–6). Indirect
approaches have also been envisaged to enhance GT by
inhibiting the expression of proteins involved in
non-homologous recombination using RNA interference
(7–9).
In the yeast, Saccharomyces cerevisiae, HR events
require both RAD51 and RAD52 proteins (10,11). In
fact, Rad51 and Rad52 deletion mutants show 4000 and
3000-fold, respectively, reductions in gene conversion of
inverted repeats as compared to the wild type (12,13).
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strand invasion mechanism that completely depends
on the human Rad51 orthologue (14), the hsRad51
overexpression stimulated GT only by 2- to 3-fold,
whereas it actually inhibited intrachromosomal recombin-
ation, suggesting that in humans Rad51 gives a relatively
modest contribution to Rad52 activity in promoting
HR via strand annealing and exchange. No appreciable
eﬀect on both mitotic and meiotic HR and on GT is
observed following hsRad51 overexpression. Conversely,
overexpression of hsRad52 in monkey cells enhances
spontaneous HR and resistance to ionizing radiation
(15). Moreover, the overexpression of hsRad52 in
human HT1080 cells inhibits GT while favoring extra-
chromosomal HR (14).
Rad52 is a multi-domain protein composed of three
regions with separate molecular functions. The
N-terminal domain is involved in DNA binding and the
C-terminal one in the interaction with the Rad51 protein,
whereas an RPA binding domain is found in between
(9,16,17). The N-terminal domain of yRad52 from
amino acid 21 to 159 is conserved from yeast to higher
eukaryotes (18). Genetic evidence in yeast indicates that
two point mutations at the N-terminus of yRad52 (Y66A
and R70A) cause a pronounced increase in the sensitivity
to ionizing radiations without signiﬁcantly aﬀecting spon-
taneous recombination. A recent report showed that the
R70A mutation actually impairs the single-stranded DNA
(ssDNA) binding activity of Rad52 aﬀecting the ﬁnal step
of gene conversion (19). Moreover, it was recently
reported that the Y66A mutant has a slow DNA
recombinational repair process (20).
The human orthologue of Rad52 is smaller than the
yeast molecule: 418 amino acids versus 471. At the
N-terminus, the human molecule lacks the ﬁrst 33 amino
acids of the yeast counterpart; amino acids 34–198 of
yRad52 share 46% homology with the N-terminus of
the human protein, whereas the C-termini of the two mol-
ecules share little or nil homology. Human and yeast
Rad52 proteins display similar physico-chemical
properties, such as the spontaneous organization in
homo-oligomeric ring structures, aﬃnity for double- and
(preferentially) ssDNA and ability to facilitate DNA
re-annealing (21).
The signiﬁcant diﬀerences in the structures of the yeast
and human Rad52 orthologue are accompanied by a
greater proneness of the yeast molecule to favor HR
(22,23). This property could therefore be exploited to
overcome the inherent limitations of hsRad52
overexpression strategies in gene therapy approaches.
Actually, we recently demonstrated that the expression
of yRad52 in human cells induces an up to 37-fold
increase of the frequency of GT and an up to 4-fold re-
duction of RI of exogenous DNA. We proposed that
yRad52 has a greater aﬃnity for ssDNA than hsRad52
and is consequently more eﬃcient in promoting strand
exchange (24). This observation suggested that the yeast
molecule could be used as a tool to develop new strategies
for gene therapy of single gene disorders. To this purpose,
we investigated the possibility of directly introducing the
molecule into the nucleus without the mediation of tran-
sient or stable transfection procedures.
In this perspective, highly relevant are the recent obser-
vations of the successful employment of membrane-
penetrating proteins or cell-penetrating peptides (CPPs),
containing protein transduction domains, for direct
transfer inside the cells of biologically active proteins,
peptides and drugs (25–27). These tools are considered
very promising for both basic research and development
of gene delivery techniques for cancer therapeutics and
vaccination (28). Recently, peptides like the cyclic
13-mer Pep42, that speciﬁcally binds the glucose-regulated
protein 78 (GRP78) and is internalized into cancer cells,
have been reported to be excellent vehicles for tumor
cell-speciﬁc chemotherapy (29). Yet, the most used CPPs
in therapeutic approaches consist of short peptides,
usually less than 30 residues, corresponding to the
membrane-permeating domain of the human immunodeﬁ-
ciency virus (HIV) Tat protein, or to VP22, penetratin,
polyarginine and transportan (30). The Tat protein,
whose fundamental role is the control of HIV-1 gene ex-
pression, possesses the unique property of entering the
cells and translocating to the nucleus when present in
the extracellular environment (25,31–33). Previous
reports showed that the addition of an 11-amino acid
stretch from the basic domain of Tat (amino acids
48–58, named tat11) to heterologous molecules, even of
a large size, mediates their cellular uptake and can deliver
in the nucleus large molecules or particles, including lipo-
somes, plasmid DNAs, phage vectors and nanoparticles
(27,34,35). This property is currently widely exploited as
a biotechnological tool for protein transduction, including
therapeutic applications like protection from apoptosis
in brain and in heart, extension of cytotoxic activity
of herpes simplex virus-1 thymidine kinase in cancer
gene therapy, and enhancement of viral-mediated gene
therapy (36–39).
We explored therefore the possibility that the addition
of tat11 to the yRAD52 protein could allow its perme-
ation into the nucleus where it could display its enhancing
eﬀect in HR events, including GT.
MATERIALS AND METHODS
Plasmids
The plasmid pQE-60-Rad52 (a gift from Rodney
Rothstein) containing the Saccharomyces cerevisiae
Rad52-His6 DNA sequence has been modiﬁed by insert-
ing, at the C-terminus of the yRAD52, the sequence
coding the arginine-rich (48–58 aa) domain from
HIV-TAT as follows: two complementary ssDNA oligo-
nucleotides carrying the DNA sequence corresponding to
the TAT domain were designed with one end sticky to the
NcoI restriction site and the other end to the EcoRI site.
The two oligonucleotides were annealed and the resulting
double strand was inserted at the NcoI–EcoRI sites to
produce the pQE60-Rad52-Tat11. The correct frame of
TAT domain insertion in RAD52 was conﬁrmed by
direct sequence analysis. The site speciﬁc point mutations
Y66A and R70A were created by using the Quick change
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ing the recommended protocol. The sequences of all oligo-
nucleotides are available upon request. The GT plasmid
pHyg
 carrying the hygromycin resistance gene mutated
at the SacII site (named hyg2) was constructed previously
by cloning the 2.2kb BamHI fragment from pTPSN into
BamHI site of Litmus 28 (New England Biolab; 24). The
plasmid pSRa-bsr-pA, kindly provided by Monica Zoppe ` ,




Plasmid pQE-Rad52-His6, pQE-Rad52-Tat11-His6 and
plasmids coding the mutated Rad52 protein (Y66A
and R70A) were introduced into Escherichia coli BL-21
competent cells. Bacterial cultures were grown in Luria
broth until OD600= 0.4 and then treated with 1mM iso-
propyl b-D thiogalactoside for 4h at 37C. All the puriﬁ-
cation steps were performed at 4C. The cells were lysed
on ice by sonication (3 cycles/3s) in 10ml equilibration
buﬀer [20mM NaH2PO4 pH 8, 400mM NaCl, 10%
glycerol, 0.1mM phenylmethylsulfonyl ﬂuoride (PMSF)]
along with lysozyme 10mg/ml (Boehringer Mannheim,
GmbH) and 5% Triton. After cell lysis, the supernatant
was collected by centrifugation. The yRad52tat11 protein
was puriﬁed by loading the supernatant onto Ni-NTA
agarose resin column that was equilibrated with the equili-
bration buﬀer prior to use. Later, the column was washed
for 4–6 times with 10ml wash buﬀer (20mM NaH2PO4
pH 8, NaCl 400mM, 20mM imidazole pH 7.8, 0.1mM
PMSF) and eluted with elution buﬀer (20mM NaH2PO4
pH 8, 400mM NaCl, 150mM imidazole pH 7.8, 5mM
MgCl2, 10% glycerol, 0.1mM PMSF). The protein was
eluted three times from the column with 800mlo f
elution buﬀer and stored at 80C. The purity and the
concentration of the yRad52 proteins was checked by
polyacrylamide gel electrophoresis, loading multiple dilu-
tions of the puriﬁed protein and comparing the band in-
tensity to known amounts of bovine serum albumin. The
ﬁnal yield of the protein was quantiﬁed using the Bradford
method (from BioRad).
DNA mobility shift assay
For this assay, we used the circular ssDNA from X174
virion purchased from New England Biolabs. The
mobility shift assay was carried out according to the
protocol previously reported (40). The reactions for
DNA mobility shift assay contained ssDNA (30mM nu-
cleotides) co-incubated with diﬀerent amounts of
wt-yRad52, mut-yRad52 or eGFPTat11 (kindly
provided by Mauro Giacca) in 10ml of reaction buﬀer
(35mM K-MOPS, pH 7.2, 1mM DTT, 100mg/ml BSA,
2.5mM ATP and 3mM Mgcl2). The reaction mixtures
were incubated at 25C for 10min and then mixed with
loading dye (0.1% Orange G in 30mM Tris–HCl, pH 7.5,
containing 50% glycerol). The mixture was loaded onto
0.9% agarose gel and separated by electrophoresis at 100
mA in TAE buﬀer at 25C until the dye front has migrated
4cm. DNA was stained with 1% ethidium bromide.
Protein delivery and immunoblotting
The yRad52tat11 was added directly to the cell culture
medium using a Multiwell
TM 24-well plate (Becton
Dickinson, NJ, USA). Increasing concentrations of
puriﬁed protein ranging from 8 to 30mg/ml were added
directly with fresh Dulbecco medium (Euroﬁn) containing
10% fetal calf serum along with 1mg/ml of chloroquine
diphosphate and incubated from 6 to 48h (31). The prep-
arations of total and nuclear extracts were carried out as
reported previously (41,42). All the steps were carried out
at 4C unless otherwise mentioned. Total cell extracts were
prepared by using lysis buﬀer containing PMSF. The
nuclear extracts were prepared by lysing the cells in hypo-
tonic buﬀer (20mM HEPES–KOH pH 8, 5mM KCl,
1.5mM MgCl2, protease inhibitors cocktail tablet pH
7.9, 5mM Na butyrate, 0.1mM DTT). The lysate was
then homogenized in a glass Dounce homogenizer and
centrifuged at 600g for 15min at 4C. The nuclei were
washed three times with nuclear extraction buﬀer
(15mM Tris–HCl pH 7.5, 1mM EDTA, 0.4M NaCl,
10% sucrose, protease inhibitors cocktail pH 7.9, 1mM
DTT). The supernatant soluble fraction was collected sep-
arately and the pellet insoluble fraction was lysed with
buﬀer containing PMSF. The concentrations of total
cellular and nuclear extracts for both soluble and insoluble
fraction were determined by BioRad Protein assay (Biorad
Laboratories, GmbH). The cell and nuclear extracts were
analyzed by SDS–PAGE electrophoresis. Puriﬁed
wt-yRad52tat11 protein was used as a control. The
membrane hybridization was carried out with mouse
monoclonal anti-penta-histidine antibody (Qiagen). The
secondary antibody used was goat secondary antimouse
IgH-HRP antibody (Santa Cruz Biotechnology). The
reference antibody for total cell extracts used was
a-tubulin mouse monoclonal antibody and goat secondary
anti-mouse IgH-HRP antibody (Santa Cruz
Biotechnology).
Intrachromosomal recombination and GT assay
To determine the eﬀect of yRAD52 in the
intrachromosomal recombination, we used the HeLaG1
cells (from Margherita Bignami) that allow to measure
gene conversion events between two diﬀerentially
mutated hygromycin-resistance (Hyg
R) genes (43). One
Hyg
R gene is mutated at the PvuI site (hyg1), the other
Hyg
R at the SacII site (hyg2, Figure 1A). An
intrachromosomal recombination event leads the restor-
ation of Hyg
R to the wild type; therefore the frequency of
intrachromosomal recombination was calculated as total
number of Hyg
R clones per 10
5 viable cells. Twenty four
or 48h after the delivery of the yRad52 protein by directly
adding the protein aliquot to the DMEM medium, the
cells were trypsinized, counted and seeded in triplicate in
10-cm dishes at cell density of 110
5/plate for recombin-
ation and in duplicate in p60mm dishes at cell density of
110
2/plate for cell survival. Hygromycin at the concen-
tration of 300mg/ml was added 24h later. Selective
medium was changed after a week. After 15 days, Hyg
R
clones and survivors were stained with crystal violet and
counted.
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HeLa1B cell line according to the previously reported pro-
cedure (24). GT events occur between a Hyg
R mutated
gene (hyg1) integrated into the genomic DNA as single
copy, and another Hyg
R copy (hyg2) transfected to the
cells by electroporation. This event leads to the reversion
of the Hyg
R to wild type. The frequency of GT was
measured as number of Hyg
R per 10
5 viable cells. In
detail, 3–510
6 cells were exposed to 16–30mgo f
yRad52 for 6h. Thereafter, cells were transfected with
10mgo fhyg2 fragment by electroporation (24). After elec-
troporation, cells were seeded in 10-cm dishes at cell
density of 110
5/plate for recombination and in
p60mm dish at cell density of 110
2/plate for cell
survival. Hygromycin (300mg/ml) was added after 24h.
Selective medium was changed after a week. After 15
days, Hyg
R clones and survivors were stained with
crystal violet and counted.
To assess whether the GT occurred, the genomic DNA
was extracted from six independent HygR clones as pre-
viously reported and PCR analysis was performed to
amplify the 359-bp fragment of the Hyg
R gene. A total
of 10ml aliquots of PCR products were digested with PvuI
as reported (24).
Random integration
The eﬀect of yRAD52 on plasmid integration was
determined in conditions allowing only non-homologous
Figure 1. Puriﬁcation, ssDNA binding activity and delivery of yRad52tat11. (A) Maps of the yRad52tat11 wild-type fusion protein, the Y66A and
the R70A mutant, that for simplicity only show the N-terminal DNA binding domain; the numbers represent amino acid residues in the wild-type
yeast molecule; the ssDNA binding domain is shown. Both mutations are located in this domain; the tat11 and the his-tag are located at the
C-terminus. (B) Coomassie staining of puriﬁed wild-type-yRad52-tat11 protein (about 52kDa); M-lane, markers; BSA-lanes 1 and 2, 200 and 400ng
of bovine serum albumin; I-lane, 5mg of total protein extract from IPTG-induced bacteria; NI-lane, 5mg of total protein extract from not induced
bacteria; WT-lanes 1, 2 and 3, wild-type yRad52tat11 puriﬁed protein elutions; the yield was 80, 70 and 50ng/ml for three diﬀerent elutions.
(C) In vitro mobility shift assay with ssDNA (30mM as nucleotides) and increasing concentrations (0.05, 0.1, 0.2, 0.3mM) of wt yRad52tat11
protein or GFPtat11 (0.3mM) as control; the reaction mixtures were loaded in a 0.9% agarose gel, electropheresed and stained with ethidium
bromide. (D) In vitro mobility shift assay with ssDNA (30mM as nucleotides) alone, in presence of 0.3mM concentration of wild-type yRad52 or
GFPtat11. (E) In vitro mobility shift assay with ssDNA (30mM as nucleotides) alone or in presence of 0.3mM concentration of wild-type
yRad52tat11, R70A or Y66A mutated protein, as indicated. (F) Western blot analysis of total cell extracts; 610
5 HeLaG1 cells were incubated
with 20mg/ml wild-type-yRad52tat11 or mutant proteins for 24h; cell lysis and total cell extracts were carried out as reported in ‘Materials and
Methods’ section; 10mg of total proteins were loaded in each well; the blot was hybridized with anti-penta-6-histidine antibody; lane 1, extract from
wild-type yRad52tat11-exposed cells; lane 2, extract from R70A treated cells; lane 3, extract from Y66A treated cells; tubulin was used as loading
control. (G) Western blot analysis of nuclear extracts from 310
6 total cells treated with 20mg/ml of wild type or mutated yRad52tat11 protein for
24h; aliquots corresponding to 10mg of nuclear protein extract were loaded and electrophoresed; lane 1, 1mg of puriﬁed yRad52tat11protein; lane 2,
nuclear extract from Y66A mutant-treated cells; lane3, nuclear extract from wild-type yRad52tat11-treated cells; lane 4, nuclear extract from R70A
mutant-treated cells.
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6 HeLa1B cells were
transfected with 4mg of pSRa-bsr-pA by electroporation
as described previously (24). The cells were seeded in
10-cm dishes at cell density of 1 10
5 cells/plate with
0.2mg/ml of blasticidin, and at a density of 110
2 in
p60mm dish for survival. The culture medium was
changed once a week and after 15 days clones were
stained and counted. The frequency of random integration
was calculated by dividing the number of blasticidin-
resistant clones by the number of viable cells.
RESULTS AND DISCUSSION
Production of the yRad52Tat11 protein and
mutant derivatives
The tat11 peptide was cloned, with the procedure
described under ‘Materials and Methods’ section, at
the C-terminus of the yRAD52 gene, to avoid any
possible interference with the ssDNA binding capacity
that resides in the N-terminus domain. We produced
also two mutants in the ssDNA binding domain
(Y66A and R70A), corresponding to ionizing
radiation-sensitive phenotypes, with a view to assess the
importance of the aﬃnity of the molecule for ssDNA, an
essential property in the context of strand exchange.
Figure 1A shows a map of the constructs utilized in this
work. yRad52Tat11 and the two mutant proteins
were puriﬁed by Ni-NTA aﬃnity column puriﬁcation
system and eluted with the buﬀer containing 20mM
imidazole and 400mM NaCl, that was proven to have
little cytotoxic eﬀect on HeLaG1 cells (around 60%
survival). SDS–PAGE analysis of the diﬀerent elutions is
reported in Figure 1B.
Aﬃnity for ssDNA of the recombinant proteins
In order to determine whether the addition of tat11
and the introduction of the point mutations aﬀect the
aﬃnity for ssDNA, we measured by a gel mobility shift
assay the ability of yRad52Tat11 and of the two single
amino acid substitution mutants (Y66A and R70A) to
bind ssDNA in vitro. In the ﬁrst place, we incubated
diﬀerent concentrations of wild-type yRad52tat11 (the
GFPtat11 protein at 0.3mM was used as control). The
highest electrophoretic motility shift was seen when
the ssDNA was mixed with 0.3mM yRad52tat11
(Figure 1C), in agreement with the eﬀect observed with
wt yRad52 at the same concentration (Figure 1D).
Accordingly, we determined the ssDNA binding activity
of the mutant yRad52tat11 proteins by adding 0.3mM
of protein that is the concentration giving the maximum
gel retardation with yRad52. The results (Figure 1C) show
that the tat11 fusion domain does not aﬀect the ssDNA
binding activity, whereas the two mutants had a much
lower aﬃnity for ssDNA (Figure 1E). Thus, the tat11
construct with the otherwise wt sequence could be ex-
ploited to determine its eﬀect on GT if introduced into
the nucleus.
Permeation of the yRad52Tat11 fusion protein into
HeLa cells and nuclei
To determine whether the tat11 peptide is actually
adequate to deliver a functional yRad52 inside the cell,
we measured the intracellular level of the yRad52tat11
and of the two mutant derivatives after incubation of
the HeLaG1 cells with the proteins at concentrations
ranging between 12 and 24mg/ml for 24h. We prepared
total cell and nuclear extracts and carried out western
blots. The three yRad52 proteins (wild type, Y66A,
R70A) were found at similar level in the total cell
extract (Figure 1E). On the other hand, the mutant
protein Y66A accumulated in the nucleus at lower level
than the wt and the R70A mutant (Figure 1F). This indi-
cates that the mutant protein Y66A is probably less stable
in intracellular conditions.
The data demonstrate that the tat11 domain fused to
Rad52 proteins is indeed able to ‘deliver’ the protein inside
the cell by crossing the membrane and reaching the
nucleus, even if the mutants do so to a lesser extent.
Enhancement of intrachromosomal recombination
In order to test whether the yRad52tat11 constructs that
have maintained to greater or lesser extent the ability to
bind ssDNA, when exogenously introduced had the same
eﬀect on the recombination processes as the intracellularly
produced protein, we ﬁrst measured the eﬃciency of
intrachromosomal recombination. To this purpose, we
used the HeLaG1 cell line which harbors two defective
hygR genes oriented as direct repeats separated by a
G418 resistance gene (43). A recombination event can
occur by gene conversion or intrachromosomal deletion
leading to the restoration of HygR gene to wild type
(Figure 2A). Hence, the frequency of intrachromosomal
recombination is measured as the frequency of HygR
clones obtained. If the clones arise from gene conversion
they must keep the NeoR gene and be resistant to G418,
whereas the HygR reversion by intrachromosomal
deletion would determine the loss of the NeoR gene and
clones would be G418 sensitive. Wt-yRad52tat11, the
mutant Y66A, or the mutant R70A protein were added
to cell culture medium at concentrations ranging between
12 and 30mg/ml and incubated at 37C for 24 or 48h. The
GFPtat11 was used as negative control. We did not
observe a signiﬁcant cytotoxic eﬀect either after 24- or
48-h incubation with the protein. The survival rate
calculated by plating 100 cells and counting the clones
after 2 weeks, ranged between 70% and 50% (data not
shown). After 24-h incubation, the wt-yRad52tat11
caused a strong increase in intrachromosomal recombin-
ation (Figure 2B). The eﬀect was measured as the fold
increase over the recombination observed with the
negative control. At 12mg/ml, yRad52 increased recom-
bination 37-fold, while the mutants stimulated recombin-
ation only 3- to 4-fold. At the concentration of 20 and
30mg/ml, the wt yRad52tat11 enhanced recombination
by 47- and 60-fold, respectively; at the same concentration
the mutant protein did not further increase recombin-
ation. After 48-h incubation (Figure 2C), at the same con-
centration range (12–30mg/ml), the wt-yRad52tat11
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the mutant proteins had only a 2- to 4-fold eﬀect.
The enhanced yield of hygromycin-resistant colonies, as
mentioned above, could in principle be due to either gene
conversion or to intrachromosomal deletion. Analysis of
the presence of the NeoR gene showed that nine HygR
clones out of ten were G418 resistant, indicating that the
90% of the recombination events are due to gene conver-
sion (43).
Thus, these results demonstrate that yRad52tat11
enhances intrachromosomal recombination by up to
60-fold without aﬀecting cell viability. These results are
to be compared with the 37-fold increase in HR previously
obtained by overexpression of yRad52 in human cells (24)
and with the actual inhibition of intrachromosomal re-
combination caused by overexpression of human Rad52
in the same cells (14). This agrees with the observed higher
eﬃciency of yRad52 versus hsRad52 in the recombination
process.
We can thus conclude that the exogenously introduced
yRad52 can indeed signiﬁcantly enhance intra-
chromosomal recombination rate. This eﬀect, not surpris-
ingly, requires the maintenance of the aﬃnity for ssDNA,
as shown by the severe reduction of recombination en-
hancement capacity demonstrated by the mutants
impaired in ability to bind ssDNA, an ability that is an
obvious prerequisite for exerting the probable strand
invasion process operated by this molecule. Actually, the
property of yRad52 to bind ssDNA is essential for
assuring its capacity to stimulate the re-annealing of com-
plementary molecules, an obligatory step for HR.
Enhancement of GT by intranuclear permeation of
yRad52 protein
To test whether the demonstrated stimulatory eﬀect of
yRad52 on intrachromosmal HR extend also to GT, con-
sidering the extensive overlap in the molecules involved in
the two processes, we used the HeLa1B cell line, which
bears a single mutated copy of hygR gene (hyg1)
integrated into the genome (24). The HeLa1B cells were
incubated for 6 hours at 37C in suspension cultures with
diﬀerent concentrations of wt-yRad52tat11 or mutant
Y66A protein, chosen since this mutation caused the
most pronounced reduction in intrachromosomal recom-
bination (Figure 2B and C). The cells were then trans-
fected by electroporation with the targeting hyg2
fragment. As shown in Figure 3A, a GT event between
hyg1 and hyg2 leads to a functional HygR gene and the
restoration of a diagnostic PvuI site in the HygR gene. The
frequency of GT is measured by the number of HygR
clones per 10
5 viable cells. The wild type yRad52tat11
strongly enhanced GT frequency in HeLa cells
(Figure 3B). At 16mg/ml, the wild-type protein increased
GT almost 9-fold over the control; at the highest concen-
tration (30mg/ml), the enhancement was over 50-fold
(Figure 3B). Also in this case, the mutant protein with
Figure 2. Eﬀect of yRad52tat11 on intrachromosomal recombination. (A) HeLaG1 cells contain two copies of HygR genes inactivated by 10-bp
insertions, either at a unique PvuI site (hyg1) or at a unique SacII site (hyg2); the two mutated hyg genes are in direct repeat orientation and are
separated by a sequence containing the amino-glycoside phosphotransferase (Neo) gene conferring resistance to G418; an intrachromosomal recom-
bination event occurring by gene conversion between the two hyg sequences results in restoration of one of the mutant hyg genes to wild type; the
intrachromosomal deletion of the DNA sequence between the two mutated hyg genes leads to the formation of a HygR wild type (Hyg WT) with
loss of intervening sequence; the intrachromosomal recombination was measured after incubating HeLaG1 cells with 12, 20 or 30mg/ml yRad52tat11
proteins for 24h (B)o r4 8 h(C). The frequency of intrachromosomal recombination was determined as total HygR clones per 10
5 viable cells; the
data are reported as mean of three to ﬁve independent experiments ± standard deviation; GFPtat11 (12, 20 and 30mg/ml) was used as negative
control (C in B and C); WT, wild-type protein; M1 and M2, Y66A and R70A mutant proteins, respectively.
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highest concentration, only by 10-fold (Figure 3B).
In order to check if the HygR clones were produced by
an accurate GT event, we isolated the genomic DNA from
six independent HygR clones, ampliﬁed the hygR
fragment and restricted with PvuI as previously reported
(24). The results showed that all clones were due to GT
because all the 359-bp fragments were digested by PvuI
giving the expected 289- and 70bp band (Figure 3C).
Thus, we can conclude that, whereas permanent expres-
sion of yRad52 in human cells caused an 37-fold en-
hancement of GT, the exogenously introduced molecule
caused an up to 50-fold enhancement of the process.
Eﬀect of intranuclear permeation of yRad52 on RI
Considering that in the case of endogenous expression the
yRad52tat11 actually decreases the frequency of RI events
by a factor of three, we investigated whether when
introduced into the cell, it aﬀects exogenous DNA inte-
gration by non homologous recombination. To this
purpose, we electroporated in HeLa cells a plasmid
DNA bearing the gene for blasticidin resistance, which
shares no homology with the chromosomal DNA, in
presence of yRad52tat11 (30mg/ml). This treatment
caused a 4.4 fold reduction in random integration fre-
quency, whereas the mutant protein caused a 2.2-fold re-
duction (Figure 3D). This eﬀect can be interpreted in the
framework of a competition between the pathways for HR
and non-homologous end-joining: the yRad52 appears to
displace the equilibrium towards HR, while also the
mutated proteins displace the equilibrium in the same
direction, but to a much lower extent. Also these data
indicate that the relatively higher eﬃciency of yRad52,
versus its human counterpart, in channeling exogenous
DNA towards GT, is maintained in the exogenously
added protein.
CONCLUDING REMARKS
The results here described show that a strategy based on
the intranuclear permeation of proteins aﬀecting DNA
transaction is potentially adequate to develop conditions
greatly, if not exclusively, favoring GT. Without such
intervention, the integration by non-homologous
Figure 3. Eﬀect of yRad52tat11 protein on GT and RI. (A) Measure of GT events between the single chromosomal HygR gene utilized in the
experiments of Figure 2 (hyg1), and the BamHI fragment transfected by electroporation to the cells, corresponding to mutant hyg2 in the same ﬁgure;
a GT event leads to the formation of wild-type HygR gene (Hyg WT) with the restoration of the restriction site PvuI. (B) GT experiment in HeLa1B
cells carried out transfecting by electroporation 10mg of BamHI hyg2 DNA fragment puriﬁed from agarose gel; cells were pre-incubated for 6h with
16, 24 or 30mg/ml yRad52tat11 or Y66A protein (M); GT frequency is expressed as total HygR clones per 10
5 viable cells and the results are the
mean of at least three independent experiments ± standard deviation. (C) The 359bp Hyg fragment was ampliﬁed by PCR from the genomic DNA
of HygR clones and digested with PvuI; the digestion gave a 289- and a 70-bp fragment; lanes 1–6, DNA from HygR clones digested with PvuI; lane
7, not restricted DNA. (D) Eﬀect of wild-type yRad52tat11 or Y66A protein (M) on random integration; the frequency of random integration was
determined in HeLa1B cells by electroporating 8mg of plasmid DNA and measured as number of total Bla
R clones per 10
4 viable cells; the results are
the mean of four independent experiments ± standard deviation.
PAGE 7 OF 9 Nucleic Acids Research, 2010,Vol.38, No. 14 e149recombination is at least 100-fold more frequent than HR.
Here, we exploited tat11 promoted permeation and the
properties of the yRad52 proteins, in the hypothesis that
this molecule, in human cells, is eﬃciently involved in the
search for homology and promotes strand invasion
thereby suppressing RI events. With this strategy we
obtained an enhancement of GT by 50-fold and a
parallel reduction of RI by 4.4-fold. In absolute terms,
therefore, the GT frequency was twice higher than RI,
to be compared to a normal situation of less than one
GT event per 100 RI ones. We propose therefore the
yRad52tat11 as a novel tool to increase GT in human
cells, to be exploited in both basic and applied research.
It is conceivable that the utilization of this strategy,
possibly exploiting also other proteins involved in DNA
transactions, may bring to the development of eﬀective
methodologies for correcting in vitro (or ex vivo) single
mutations involved in monogenic disorders.
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